Larimar Therapeutics, Inc. LRMR announced that the FDA has removed the partial clinical hold on its nomlabofusp (CTI-1601) ...

Larimar Therapeutics announces FDA lift of partial clinical hold on nomlabofusp (CTI-1601) for Friedreich's Ataxia. Data from ...

BALA CYNWYD, PA — Larimar Therapeutics, Inc. (Nasdaq: LRMR) announced this week that the U.S. Food and Drug Administration ...

Food and Drug Administration (FDA) removed partial clinical hold following review of Phase 2 dose exploration study data ...

Leerink Partners raised the price target for the Larimar Therapeutics Inc (NASDAQ:LRMR) stock to “an Outperform”. The rating was released on April 03, 2024, according to finviz. The research report ...

Larimar will continue the open label extension study in Friedreich’s ataxia with results expected in Q4 this year.

Larimar Therapeutics’ Friedreich’s ataxia program is free at last, with the FDA fully lifting a clinical hold that had ...

As of May 17, 2024, Larimar Therapeutics Inc had a $474.0 million market capitalization, putting it in the 53rd percentile of companies in the Biotechnology & Medical Research industry. Larimar ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...

(RTTNews) - Larimar Therapeutics, Inc. (LRMR) Tuesday announced that FDA has removed the partial clinical hold placed on its nomlabofusp or CTI-1601, a clinical program targeting treatment of patients ...

First patient dosed in open label extension (OLE) study with 25 mg daily dosing of nomlabofusp; interim data on track for Q4 ...